Skip to main content
. 2021 Jun 1;15(12):3447–3467. doi: 10.1002/1878-0261.12998

Fig. 7.

Fig. 7

Synergistic effect of EMD and bevacizumab in CRC PDX models. (A, B) Growth curves and tumor weight of PDX model tumors after treatment with vehicle, EMD, or/and bevacizumab. (n = 4) (C, D) H&E, PAS, and CD31 staining in PDX model tumors after treatment with vehicle, EMD, or/and bevacizumab. Black scale bars = 200 μm; white scale bars = 20 μm, n = 4. (E, F) Statistics of PAS+/CD31− VM channels and PAS−/CD31+ channels in PDX model tumors after treatment with vehicle, EMD or/and bevacizumab. Values are represented as mean ± SD. NC, negative control. NS, no significant, *P < 0.05, **P < 0.01, ***P < 0.001, by one‐way ANOVA (A, B, E, F).